TY - JOUR
T1 - Development and testing of a tailored online fertility preservation decision aid for female cancer patients
AU - van den Berg, Michelle
AU - van der Meij, Elleke
AU - Bos, Annelies M. E.
AU - Boshuizen, Marieke C. S.
AU - Determann, Domino
AU - van Eekeren, Ramon R. J. P.
AU - Lok, Christianne A. R.
AU - Schaake, Eva E.
AU - Witteveen, Petronella O.
AU - Wondergem, Marielle J.
AU - Braat, Didi D. M.
AU - Beerendonk, Catharina C. M.
AU - Hermens, Rosella P. M. G.
N1 - Funding Information: This work was supported by the Radboud University Medical Center. Publisher Copyright: © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Background: Decision making regarding future fertility can be very difficult for female cancer patients. To support patients in decision making, fertility preservation decision aids (DAs) are being developed. However, to make a well-informed decision, patients need personalized information tailored to their cancer type and treatment. Tailored cancer-specific DAs are not available yet. Methods: Our DA was systematically developed by a multidisciplinary steering group (n = 21) in an iterative process of draft development, three rounds of alpha testing, and revisions. The drafts were based on current guidelines, literature, and patients' and professionals' needs. Results: In total, 24 cancer-specific DAs were developed. In alpha testing, cancer survivors and professionals considered the DA very helpful in decision making, and scored an 8.5 (scale 1–10). In particular, the cancer-specific information and the tool for recognizing personal values were of great value. Revisions were made to increase readability, personalization, usability, and be more careful in giving any false hope. Conclusions: A fertility preservation DA containing cancer-specific information is important in the daily care of female cancer patients and should be broadly available. Our final Dutch version is highly appraised, valid, and usable in decision making. After evaluating its effectiveness with newly diagnosed patients, the DA can be translated and adjusted according to (inter)national guidelines.
AB - Background: Decision making regarding future fertility can be very difficult for female cancer patients. To support patients in decision making, fertility preservation decision aids (DAs) are being developed. However, to make a well-informed decision, patients need personalized information tailored to their cancer type and treatment. Tailored cancer-specific DAs are not available yet. Methods: Our DA was systematically developed by a multidisciplinary steering group (n = 21) in an iterative process of draft development, three rounds of alpha testing, and revisions. The drafts were based on current guidelines, literature, and patients' and professionals' needs. Results: In total, 24 cancer-specific DAs were developed. In alpha testing, cancer survivors and professionals considered the DA very helpful in decision making, and scored an 8.5 (scale 1–10). In particular, the cancer-specific information and the tool for recognizing personal values were of great value. Revisions were made to increase readability, personalization, usability, and be more careful in giving any false hope. Conclusions: A fertility preservation DA containing cancer-specific information is important in the daily care of female cancer patients and should be broadly available. Our final Dutch version is highly appraised, valid, and usable in decision making. After evaluating its effectiveness with newly diagnosed patients, the DA can be translated and adjusted according to (inter)national guidelines.
KW - cancer
KW - decision aid
KW - fertility preservation
KW - shared decision making
KW - tailored information
UR - http://www.scopus.com/inward/record.url?scp=85101463477&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/cam4.3711
DO - https://doi.org/10.1002/cam4.3711
M3 - Article
C2 - 33580749
SN - 2045-7634
VL - 10
SP - 1576
EP - 1588
JO - Cancer Medicine
JF - Cancer Medicine
IS - 5
ER -